Aurobindo Pharma's CuraTeQ Secures Health Canada Approval for Cancer Biosimilar
Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilar
The Economic Times
Image: The Economic Times
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a compliance notice from Health Canada for its bevacizumab biosimilar, Bevqolva, used in cancer treatment. This approval confirms the biosimilar meets safety and efficacy standards, allowing it to be marketed in Canada.
- 01CuraTeQ Biologics received Health Canada's approval for its bevacizumab biosimilar, Bevqolva.
- 02The biosimilar is indicated for the treatment of various cancers.
- 03Bevqolva is available in 100 mg and 400 mg formulations.
- 04The originator product, Avastin, is marketed by Roche/Genentech.
- 05CuraTeQ has two additional biosimilar applications under review.
Advertisement
In-Article Ad
Aurobindo Pharma announced that its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health Canada's Biologics and Radiopharmaceutical Drugs Directorate for its biosimilar, Bevqolva, which is a version of the cancer treatment bevacizumab. This notice signifies that the biosimilar has passed a successful review and meets the necessary regulatory standards for safety, efficacy, and quality, allowing it to be marketed in Canada. Bevqolva is available in 100 mg and 400 mg formulations and is indicated for treating various cancers, including colorectal and lung cancer. The original drug, Avastin, is produced by Roche/Genentech. Additionally, CuraTeQ Biologics has two more biosimilar applications currently under review by Health Canada.
Advertisement
In-Article Ad
The approval of Bevqolva may increase treatment options for cancer patients in Canada, potentially leading to lower costs compared to the original drug.
Advertisement
In-Article Ad
Reader Poll
Do you think biosimilars like Bevqolva will improve access to cancer treatments?
Connecting to poll...
Read the original article
Visit the source for the complete story.